Aileron Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Rein Therapeutics

10/05/2022 21:42

* Aileron Therapeutics Inc  ALRN.OQ  reported a quarterly
adjusted
loss of 9 cents​​ per share for the quarter ended in March. The
mean expectation of three analysts for the quarter was for a
loss of 8 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Aileron Therapeutics Inc's reported EPS for the quarter
was a
loss of 9 cents​.
    * The mean earnings estimate of analysts had risen by
about 27% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Aileron Therapeutics Inc shares had fallen by 25.6% this
quarter and lost 32.3% so far this year.
    * The company reported a quarterly loss of $8.42 million.
    * Wall Street's median 12-month price target for Aileron
Therapeutics Inc is $3.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 10 at 08:41 p.m.  ​All
figures in US dollars unless otherwise stated